SMOS-NEXT: A New Concept for Soil Moisture Retrieval from Passive Interferometric Observations

This book is a collection of 19 articles which reflect the courses given at the Collège de France/Summer school “Reconstruction d'images − Applications astrophysiques“ held in Nice and Fréjus, France, from June 18 to 22, 2012. The articles presented in this volume address emerging concepts and methods that are useful in the complex process of improving our knowledge of the celestial objects, including Earth

SMOS-NEXT: A New Concept for Soil Moisture Retrieval from Passive Interferometric Observations

Present soil moisture and ocean salinity maps retrieved by remote sensing are characterized by a coarse spatial resolution. Hydrological, meteorological and climatological applications would benefit greatly from a better spatial resolution. Owing to the dimensions of the satellite structure and to the degradation of the instrument’s radiometric sensitivity, such improvement cannot be achieved with classical interferometry. Then, in order to achieve this goal an original concept for passive interferometric measurements is described. This concept should allow to achieve a much finer spatial resolution, which can be further improved with the application of disaggregation methods. The results will then allow the integration of global soil moisture maps into hydrological models, a better management of water resources at small scales and an improvement in spatial precision for various applications

Interaction Mechanisms Between Ar–O2 Post-Discharge and Stearic Acid I: Behaviour of Thin Films

International audienc

Interaction Mechanisms Between Ar–O2 Post-Discharge and Stearic Acid II: Behaviour of Thick Films

International audienc

Treatments outcomes in histological variants and non-urothelial bladder cancer: results of a multicenter retrospective study

Introduction: Less than one-third of bladder cancers are non-pure urothelial carcinoma [with variant histological (VH) or non-urothelial carcinoma (non-UC)] for which no treatment guidelines are available. We aim to evaluate the efficacy of systemic treatments in VH or non-UC bladder cancers. Materials: Multicenter retrospective analysis of patients treated for advanced or metastatic VH or non-UC bladder cancers. Primary endpoint was overall response rate (ORR) according to treatment line, regimen and histology subtype. Secondary endpoints were progression-free survival (PFS) and overall survival (OS). Results: Between 2005 and 2020, 46 patients from seven centers were included. The median age was 66 years (58.75; 74.75), 65.2% were male and 67.2% presented VH. At first line, the ORR for the entire population was 54.4% and median OS was 21.6 months (95% confidence interval [CI]: 14.2-38.6). The ORR of the 37 patients treated with chemotherapy at first line was 62.2% with median PFS and OS of 7.3 (95% CI: 4.5-8.6) and 21.6 months (95% CI: 14.2-35.7), respectively. Dose dense MVAC and platinum doublet chemotherapy had the highest ORR (71.4% and 65.2%). The 9 patients treated with immunotherapy at first line had an ORR of 22.2%, a median PFS of 3.3 months (95% CI:2.3-NR) and the median OS was not reached (95% CI:13.8-NR). Response to treatment varied depending on the histological sub-types and on the treatment type. Conclusion: Chemotherapy and immunotherapy have shown to be effective in VH or non-UC cancers, a rare histological subtype for which we currently have very little data in the literature

1158P Study of patients’ characteristics associated with osimertinib outcomes upfront or in following lines in EGFR-positive NSCLC

BACKGROUND : In first line (L1) for EGFR-mutated (mEGFR) advanced NSCLC (aNSCLC), osimertinib (osi) has been the preferred option since 2018. First generation anti-EGFR TKI (1G) alone followed by osi, or 1G + anti-angiogenic or 1G + chemotherapy are other options. We aimed to assess the subgroups of patients (pts) that do not benefit from 1G alone compared with osimertinib L1 in mEGFR aNSCLC. [...